Lilly/Sankyo prasugrel enters Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly/Sankyo's antiplatelet agent prasugrel (CS-747) is slated to begin Phase III trials by year-end. TRITON-TIMI-38 will compare prasugrel to Plavix in 13,000 acute coronary syndrome patients undergoing percutaneous coronary intervention. Prasugrel is designed to prevent platelet activation by blocking adenosine diphosphate receptors on platelet surfaces...